drugset / Trial / NCT04335305
Checkpoint Blockade in COVID-19 Pandemic
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, randomized, controlled, open-label, phase 2 clinical trial
Timeline
- Start
- 2020-04-09
- Primary completion
- 2021-03-08
- Completion
- 2021-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |